Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Entero Therapeutics (ENTO).
Entero Therapeutics, Inc. announced that Dr. Jack Syage, the Chief Scientific Officer, has resigned from his position effective immediately as part of the company’s cost-cutting measures. However, he will maintain his roles as President and Board member. Dr. Syage has agreed to a reduced annual salary of $66,560 starting July 1, 2024, but all other compensation and employment terms remain unchanged. His resignation is not due to disagreements with the company’s direction or practices.
For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.